Please login to the form below

Not currently logged in
Email:
Password:

Selexys

This page shows the latest Selexys news and features for those working in and with pharma, biotech and healthcare.

Novartis buys blood disease specialist Selexys

Novartis buys blood disease specialist Selexys

Novartis has bolstered its portfolio with a deal to buy US company Selexys Pharmaceuticals, which has a drug for sickle cell disease heading for phase III. ... The Swiss pharma major is paying up to $665m for Selexys, including upfront, acquisition and

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    Options exercised. The largest deal in our table this month is the acquisition of Selexys Pharmaceuticals by Novartis for $665m in upfront, acquisition and milestone payments. ... Licensor Acquired/ Licensee Acquirer. Product/ Technology. Deal Type.

  • Pharma deals during September 2012 Pharma deals during September 2012

    Last but not least. The final deal under the spotlight this month is Novartis' option to acquire Selexys Pharmaceuticals upon successful phase II studies in SelG1, a humanised mAb targeting ... Dual-affinity re-targeting (DART) platform technology for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics